Skip to main content
Signal8

DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent

$DVLTPress releaseNov 3, 2026, 6:18 PM ETRead the release

DataMEDS AI (NASDAQ: MEDS) terminated the Second Amended and Restated letter of intent dated October 19, 2026 with Datavault AI (NASDAQ: DVLT) and four other parties covering in-license or acquisition of IP in exchange for DataMEDS common stock, citing market conditions. DVLT will no longer receive shares under the terminated LOI, and DataMEDS states it owes no fees or obligations as a result of the termination.

Key figures

Loi date
October 19, 2026
Loi termination fee
0
Related agreements preserved
["REBOOT exclusive GLP-1 management license (Oct 13, 2026)","Datavault AI PharmacyChain agreement (Nov 24, 2025)"]

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    DVLT: DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent — AI Analysis | Signal8